BILL to Participate in Upcoming Investor Conferences
Get Alerts BILL Hot Sheet
Join SI Premium – FREE
SAN JOSE, Calif.--(BUSINESS WIRE)-- BILL (NYSE: BILL), a leader in financial automation software for small and midsize businesses (SMBs), today announced its participation in the following upcoming investor conferences:
Deutsche Bank Technology Conference
Wednesday, August 30, 2023 at 10:15am PT
Goldman Sachs Communacopia + Technology Conference
Wednesday, September 6, 2023 at 9:30am PT
Piper Growth Frontiers Conference
Tuesday, September 12, 2023 at 11:00am PT
Autonomous Future of Commerce Symposium
Thursday, September 14, 2023 at 9:15am PT
Live webcasts, as well as replays, will be available on the Company's investor relations website at https://investor.bill.com/. Please note presentation times are subject to change.
About BILL:
BILL (NYSE: BILL) is a leader in financial automation software for small and midsize businesses (SMBs). As a champion of SMBs, we are automating the future of finance so businesses can thrive. Hundreds of thousands of businesses rely on BILL to more efficiently control their payables, receivables and spend and expense management. BILL’s network connects millions of members so they can pay or get paid faster. Headquartered in San Jose, California, BILL is a trusted partner of leading U.S. financial institutions, accounting firms, and accounting software providers. For more information, visit bill.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230828039221/en/
IR Contact:
Karen Sansot
[email protected]
Press Contact:
John Welton
[email protected]
Source: BILL
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Align Technology Prevails in China Patent Infringement Action Against Angelalign
- Optimal Transit Unveils Second Configuration of the Kraaken™ Data Center: A Ship That Can Power 32,000 Homes, Produce Clean Water for 150,000 People, and Host 60 MW of AI Compute – With No Fuel an
- New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Deutsche Bank, Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share